12:00 AM
 | 
Sep 07, 1999
 |  BC Week In Review  |  Company News  |  Deals

GPC AG, Novalon deal

The companies will develop broad spectrum antibiotics using GPC's genomics-derived antibacterial targets. Novalon will screen small molecule...

Read the full 63 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >